Aripiprazole inhibits superoxide generation from phorbol-myristate-acetate (PMA)-stimulated microglia in vitro:

Takahiro A Kato1, Akira Monji, Keiji Yasukawa

  • 1Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Fukuoka 812-8582, Japan. takahiro@npsych.med.kyushu-u.ac.jp

Schizophrenia Research
|April 19, 2011
PubMed

Insights

Aripiprazole, an atypical antipsychotic, reduces superoxide generation in activated microglia, a key factor in schizophrenia. This antioxidant effect may explain its therapeutic benefits by protecting neurons from oxidative damage.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Cell Biology

Background:

  • Schizophrenia is linked to altered antioxidant status and microglial activation.
  • Microglia produce superoxide (•O(2)(-)), a free radical implicated in brain pathologies.
  • Atypical antipsychotics, like aripiprazole, may influence microglial activity.

Purpose of the Study:

  • To investigate the antioxidative effects of antipsychotics on microglial superoxide generation.
  • To elucidate the intracellular mechanisms underlying aripiprazole's effects on microglia.
  • To examine the impact of aripiprazole on microglial-induced neuronal damage.

Main Methods:

  • Electron spin resonance (ESR) spectroscopy to measure superoxide generation in phorbol-myristate-acetate (PMA)-stimulated microglia.
  • Intracellular Ca(2+) imaging and immunostaining to analyze intracellular mechanisms.
  • Co-culture experiments to assess microglial-induced neuronal damage.

Main Results:

  • Aripiprazole significantly inhibited superoxide generation in PMA-stimulated microglia.
  • Aripiprazole's inhibitory effect involved protein kinase C (PKC) activation, Ca(2+) regulation, and NADPH oxidase activation.
  • Aripiprazole pretreatment attenuated neuritic beading, a marker of neuronal damage induced by activated microglia.

Conclusions:

  • Aripiprazole exhibits antioxidative effects by reducing microglial superoxide production.
  • This mechanism, involving modulation of oxidative stress and neuronal protection, offers a novel therapeutic hypothesis for schizophrenia.
  • Aripiprazole's unique D2 receptor partial agonism may contribute to its efficacy through these neuroprotective pathways.